From Bio

At a glance

From Bio filed 33 disclosures in the last 12 months, including 5 5% holder and 4 insider. The most recent key filing was on Sep 18.

Revenue for 2025 was ₩72.2B, up 7.4% on 2024. It made an operating loss of ₩18.6B. Debt was 150% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩33.8B and operating loss of ₩3.8B.

The 2025 annual report lists 147 employees with an average tenure of 2.3 years and average pay of ₩37.9M, #1780 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩160M each on average. It paid no cash dividend for 2025. 심태진 and related parties held 40.35% at year end.

From the 2025 annual report

Staff: 147 (64 men, 83 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩5.6B. Directors and auditors: 7, paid ₩1.1B in total.

No cash dividend was paid for 2025.

Largest shareholder

심태진 holds 36.06%; with 5 related parties the group holds 40.35% of common shares at year end (from 40.42% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary